The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Agreed and whilst the OAM sales will not be helping the sp their reason for selling is not related to avo's current financing difficulties and it does look like someone is happy to pick them up. As mentioned the French counterparty could be holding onto their very large accumulation. Difficult to read into what this all means but hoping it is a sign of a positive outcome....why else would anyone buy all these shares and not to forget the large investments recently made by significant shareholders including Board members. Trying to remain positive but feeling like a piece of wizardry like a light machine is required.
Maybe Lars is wielding the big axe for the chop when you don't hit the numbers. Might sharpen things up with the forecasting to sales ratio a good sign I think hopefully he'll bring someone in that actually sells something.
If avo manage to pull a rabbit out of the hat someone has managed to accumulate a substantial number of shares from OAM's difficulties. At these ridiculously low levels you fear the worst but with every substantial sale being bought perhaps there is hope. Not long left of the current finance so expecting news either way very soon. Still can't quite believe what they are sat on is valued so cheaply, the CERN developed RFQ is probably worth more!
Not trying to defend the BoD other than acknowledging that some have invested substantial funds. Don't think the warrants the BoD have received come with the compensatory shares as per the french counterparty.
All these cheap shares along with OAM forced into selling is compounding an already difficult situation. When it rains it pours but I'm hoping like the current weather we start to see some sunshine. Not sure what your investment here is but good luck as we all need it in this market.
As ever all looks so promising but nothing will count for anything until they start selling and deliver the numbers apart from a positive outcome in the court case. I will not be impressed if all we hear about is ex murata orders. The team should be focussed on winning new business across the complete product range not bloody taking orders from ex murata customers I'd do that job on a commission only basis. Lars better be wielding the big stick and get some of these large cap modules sold looking forwards to hearing a different tone from him in the EoY results I hope.
These conversions don't make for good reading must be like a kick in the teeth for the heavily invested BoD and lth's of which I am one. The only good thing is that as long as they aren't selling they see a profit in holding onto the shares which indicates some sort of deal will be agreed. If it is somehow I think it will be a long time before I see any profit but always intended to hold until successfully commercialised so will reassess then but fingers crossed for now!
Richar I couldn't agree more they just argue amongst themselves all day everyday. I thought the same thinking they're all sat in the same room messaging each other. Definitely would be very careful about the perception created through this dialogue might be far fetched but starting to think they pat each other on the back at the end of the day for a job well done.
Is it possible there could be a phase 1a US STS patient that would normally be treated with dox that was dosed in cohort 5 and continues to cohort 6 and eventually continues to phase 1b as their disease has not progressed. They would then have very early efficacy details almost from the outset of phase 1b.
I can't imagine the patients where disease hasn't progressed being denied continuation of treatment and all the data immediately available will be of tremendous value. Understandably all the other phase 1b regulatory data and comparative studies will be needed but there will be no denying the evidence in front of them on completion of phase 1a.
That would be fantastic news but I'm not so sure it is imminent. Money was required for additional building works to create the necessary patient facilities and UHB have a list of tasks to complete. Whether all of this is continuing at pace without long term funding set up is unclear. When the BoD gave a timescale of H2 2023 for 1st patient treatment from past experience we'll be fortunate if it happens in December and that's without the difficulties created by not having sufficient funds in place.
My hope is we get news of a satisfactory funding arrangement by end of this month with an operational update to detail progress from the last update but would not be surprised to hear of slippages. Having said that just the funding would stabilise the sp which has turned into a bigger risk than the unbelievably complex task of reaching 230MeV.
24th July as far as I'm aware. Latest update below have no idea what they mean but inspite of most cases being settled this is going to the wire.
Thursday, June 22, 2023
256 notice Notice - Other Thu 06/22 3:15 PM
NOTICE of /Defendant's Notice Pursuant to 35 U.S.C. § 282 by Maxwell Technologies, Inc. (Morrison, Susan)
Good luck with your holding you must have a great average. I've got way too much in these at a much much higher price and starting to hope for a miracle.
Everything has been said about the wonderful technology & huge potential seemingly close to ruin due to the dire financial situation. Considering mr serandour's background is in finance he seems to have been caught out like an ordinary mug. I know world events have been difficult and the response to achieving 230MeV the complete opposite of what they must have been expecting but there seems no contingency was in place. Hopefully someone comes to the rescue and credit to the board members who have continued with financial support but I'm starting to wonder about the value of the leadership steering the ship into this mess.
Yep I follow that I was just interested in the decision to convert now as the maturity date is February 2025. I suppose receiving around 3m shares instead of £150k cash is quite an easy one to make with £2.75m still outstanding. The thing is if I believed a positive outcome regarding funding would boost the sp I'd convert the remaining loan and would be sat with 65m shares. At just 10p a share that's £6.5m over 100% return. Alternatively if it all fails the shares will be worthless, not sure about loan notes in a worst case scenario. Probably difficult to read into what these early conversions could mean and we're just going to have to wait until the communication arrives but all these warrants and loan notes are not helping the sp.
Is it possible that some of the US patients have cancer types that would be receptive to dox and therefore quite likely to see efficacy but also great news about earlier cohorts extended treatment without disease progression as we already know the poor prognosis they had.
absolutely jt and it's all to do with aim a failing market where despicable individuals like tw can play their games, raising funds on the back of progress is like burning money and long term investments can be destroyed by what appears to be manipulation. i'm sure this will succeed and when it does if it still lives in this ****hole i and many others will head for the exit door never to return.
Any thoughts on why the conversions kenj. I can only assume that whilst they can opt to have the loan repaid in cash obtaining all these shares will be more profitable assuming a satisfactory deal is secured. I'm sure they have a better insight in to what is going on than PI's so I'm hopeful this is a positive sign rather than just profiteering from what looks like a slight oversight from the BoD in setting up this arrangement.
Https://cerncourier.com/a/cerns-impact-on-medical-technology/
Probably a better article to get an appreciation of their involvement in proton therapy with both avo and ugo amaldi being mentioned. There will be many interested parties wanting this to succeed.
Who knows but it all seems a bit of a mess at present. If you read the attached article and see the numbers involved and the contribution that cern are hoping to achieve in medical imaging amongst other things it seems inconceivable that this breakthrough technology with Light will not be commercialised. Just need the avo BoD to manage the solution to the benefit of lth otherwise all these years and over 250m of investment will be snapped up for a pittance.
https://www.forbes.com/sites/alexknapp/2012/07/05/how-much-does-it-cost-to-find-a-higgs-boson/